Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002410 · ClinicalTrials.gov registry record · Phase 3
A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients
A Phase 3 study of HIV Infections, sponsored by Dupont Merck.
- Completed
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
NCT00002410: Completed Phase 3 study of HIV Infections, sponsored by Dupont Merck.
NCT00002410 is a Phase 3 study of HIV Infections that has completed, run by Dupont Merck. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002410, a Phase 3 study of HIV Infections, has completed, sponsored by Dupont Merck.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 20
- Study locations
Study Summary
The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the resistance HIV may have to these drugs and if these drugs are effective over a long period of time.
Conditions Studied
Interventions
- DRUG Zidovudine
- DRUG Lamivudine
- DRUG Indinavir sulfate
Study Locations (20)
Florida
- Bach and Godofsky - Bradenton
- Community Research Initiative of South Florida - Coral Gables
- Boulevard Comprehensive Care Ctr - Jacksonville
- Larry Marc Bush / c/o Sally Yantis - Lake Worth
- Univ of Miami School of Medicine - Miami
- Ctr for Quality Care - Tampa
- Daniel Seekins - Tampa
- Infectious Disease Research Institute - Tampa
- Treasure Coast Infectious Disease Consultants - Vero Beach
California
- Richard Stryker - Beverly Hills
- Paul Cimoch - Irvine
- AIDS Healthcare Foundation - Los Angeles
- Kraus Med Group - Los Angeles
- Oasis Clinic / Martin Luther Jr Gen Hosp / King-Drew Med Ctr - Los Angeles
Arizona
- Phoenix Body Positive - Phoenix
- Arizona Clinical Research Ctr Inc - Tucson
Georgia
- Georgia Research Associates - Atlanta
- Med College of Georgia - Augusta
Connecticut
- Blick Med Associates - Stamford
District of Columbia
- Novum Inc - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002410
The ClinicalTrials.gov registry entry for NCT00002410 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Dupont Merck, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002410 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00002410 about?
NCT00002410 is a clinical study titled "A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients". The purpose of this study is to compare the safety and effectiveness of three anti-HIV drug combinations. The three combinations are: (1) efavirenz (DMP 266) plus indinavir; (2) DMP 266 plus zidovudine (ZDV) plus lamivudine (3TC); and (3) indinavir plus ZDV plus 3TC. This study also examines the res...
What is the current status of trial NCT00002410?
This trial is currently completed. It is a Phase 3 study.
What conditions does trial NCT00002410 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002410?
The interventions under investigation include: Zidovudine (DRUG), Lamivudine (DRUG), Indinavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002410?
This trial is sponsored by Dupont Merck, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002410 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + Rilpivirine (RPV) LA When Given to Participants With Detectable HIV-1
RECRUITING · Phase 3
-
Testing a Real-time Electronic Antiretroviral Adherence Monitoring Intervention
RECRUITING · Phase 3
-
SmartSteps: A Context-Aware, PrEP Adherence Intervention for Individuals With Substance Use Disorder
RECRUITING · Phase 3
-
Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine From Current Antiretroviral Regimen in Virologically Suppressed HIV-1-infected Adults
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
The LATITUDE Study: Long-Acting Therapy to Improve Treatment SUccess in Daily LifE
ACTIVE NOT RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.